IGFBP-3

GHAKDSQRYKVDYESQSTDTQNFSSESKRETEYGPCRREMEDTLNHLKFLNVLS
PRGVHIPNCDKKGFYKKKQCRPSKGRKRGFCWCVDKYGQPLPGYTTKGKEDVH
CYSMQSK

KVDYESQSTDTQNFSSESKRETEYGPCRREMEDTLNHLKFLNVLSPRGVHI
PNCDKKGFYKKKQCRPSKGRKRGFCWCVDKYGQPLPGYTTKGKEDVHCYSMQSK

HPLHSKIIIIKKGHAKDSQRY

IGFBP-4

DEAIHCPPCSEEKLARCRPPVGCEELVREPGCGCCATCALGLGMPCGVYTPRCG
SGLRCYPPRGVEKPLHTLMHGQGVCMELAEIEAIQESLQPSDKDEGDHPNNSFSP
CSAHDRRCLQKHFAKIRDRSTSGGKM

KVNGAPREDARPVPQGSCQSELHRALERLAASQSRTHEDLYIIPIPNCDRNGNFHP
KQCHPALDGQRGKCWCVDRKTGVKLPGGLEPKGELDCHQLADSFRE

IGFBP-5

LTQSKFVGGAENTAHPRIISAPEMRQESEQGPCRRHMEASLQELKASPRMVPRA
VYLPNCDRKGFYKRKQCKPSRGRKRGICWCVDKYGMKLPGMEYVDGDFQCHTF
DSSNVE

KFVGGAENTAHPRIISAPEMRQESEQGPCRRHMEASLQELKASPRMVPRAVY
LPNCDRKGFYKRKQCKPSRGRKRGICWCVDKYGMKLPGMEYVDGDFQCHTFDS
SNVE

HTRISELKAEAVKKDRRKKLTQS

IGFBP-6

PQAGTARPQDVNRRDQQRNPGTSTTPSQPNSAGVQDTEMGPCRRHLDSVLQQ
LQTEVYRGAQTLYVPNCDHRGFYRKRQCRSSQGQRRGPCWCVDRMGKSLPGS
PDGNGSSSCPTGSSG,

and cyclic, glycosylated, phosphorylated, acetylated, amidated and/or sulfated derivatives thereof.

17. A method for the preparation of the peptides according to claim 16 by purification from human hemofiltrate or urine, by solid-phase peptide synthesis, or by expression in recombinant microorganisms.

18. Complexes of peptides according to claim 16 with hIGF-I (human insulin-like growth factor I, MW 7649) or hIGF-II (human insulin-like growth factor II, MW 7491) and its biologically active fragments and/or derivatives, especially amidated, acetylated, sulfated, phosphorylated and/or glycosylated derivatives.

19. A nucleic acid, characterized by coding for peptides according to claim 16.

20. Antisense nucleotide, characterized by binding, under stringent conditions, to a nucleic acid sequence coding for a peptide according to claim 16.

21. Antibody, characterized by binding to a peptide according to claim 16.

22. Inhibitor, characterized by inhibiting the biological activity of peptides according to claim 16.

23. Inhibitor, characterized by inhibiting the expression of peptides according to claim 16.

24. Use of peptides according to claim 16, for the preparation of a medicament for treating the underexpression of insulin-like growth factor binding proteins.

25. Use of antisense nucleotides according to claim 20, for the preparation of a medicament for treating the overexpression of insulin-like growth factor binding proteins.